YOLFTbeta
08

Peptron Inc

087010 · KQ · Healthcare / Biotechnology & Medical Research

92,700.00KRW-4300.00 (-4.43%)

Price History

Full chart

Market Stats

Previous Close97,000.00
Open98,000.00
Day Range92,100.00 – 101,200.00
52-Week Range79,200.00 – 392,500.00
Volume147.44K
Market Cap2.15T
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.74
50-Day Avg136,156.00
200-Day Avg213,550.00

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology & Medical Research
  • CEOMr. Ho-Il Choi
  • Employees0
  • Headquarters37-24, Yuseong-daero 1628 beon-gil, Daejeon, South Korea, 340-54, Korea
  • Websitehttp://www.peptron.co.kr

Leadership

  • Mr. Ho-Il ChoiChief Exec. Officer

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.48B2.81B3.13B3.22B3.86B1.80B3.12B6.62B5.81B3.34B3.15B5.63B
Growth (%)-+13.24%+11.32%+2.70%+20.10%-53.36%+73.26%+112.28%-12.24%-42.52%-5.68%+78.76%
Cost of Revenue1.39B1.89B1.91B2.00B2.41B1.14B1.98B2.08B2.49B2.20B2.04B4.10B
Gross Profit1.09B917.49M1.22B1.22B1.45B656.65M1.14B4.54B3.32B1.14B1.11B1.53B
Gross Margin44.02%32.62%39.01%37.87%37.57%36.46%36.41%68.58%57.10%34.13%35.13%27.18%
Operating Expense3.70B3.77B4.79B6.17B9.36B13.36B18.92B20.22B18.57B17.03B17.64B22.79B
Operating Income-2.61B-2.85B-3.56B-4.95B-7.91B-12.70B-17.78B-15.67B-15.25B-15.89B-16.54B-21.26B
Operating Margin-105.06%-101.34%-113.86%-153.99%-204.81%-705.32%-569.72%-236.61%-262.23%-475.51%-524.61%-377.25%
EBITDA---------9.73B-12.65B-18.46B-10.29B
EBITDA Margin---------167.41%-378.54%-585.48%-182.63%
Net Income-3.05B-2.73B-3.19B-4.43B-3.73B-17.72B-18.38B-15.04B-15.06B-15.92B-22.03B-13.82B
Net Income Margin-122.66%-97.09%-101.93%-137.68%-96.48%-983.70%-589.03%-227.07%-259.08%-476.43%-699.00%-245.33%
R&D1.99B2.01B2.77B3.74B6.07B9.84B14.18B14.84B13.37B11.44B12.14B15.45B
R&D as % of Total Revenue80.16%71.33%88.53%116.23%157.16%546.06%454.39%224.04%229.92%342.43%384.99%274.15%
Interest Expense000000036.84M279.66M396.04M472.88M1.32B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.56%4.81%11.85%15.00%23.44%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.58B21.66B57.90B53.05B71.76B60.99B117.70B77.87B68.27B52.50B168.89B178.98B
Total Liabilities4.39B4.43B4.69B4.10B26.66B32.90B40.57B15.59B15.17B16.37B17.18B36.97B
Total Equity6.48B17.23B53.21B48.95B45.10B28.09B77.13B62.28B53.11B36.13B151.71B142.01B
Cash460.78M602.19M3.53B955.86M1.80B2.45B67.96B4.64B5.04B4.26B1.05B4.38B
Total Debt--2.00B2.00B-29.16B9.14B-----
Net Debt-----26.67B-4.41B4.01B4.78B8.00B24.71B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.86B-2.36B-2.73B-5.63B-4.18B-9.60B-13.55B-10.61B-11.72B-10.97B-12.77B-20.59B
Investing Cash Flow-4.79B-10.09B-33.39B3.27B-20.54B9.20B5.48B-25.88B12.07B11.04B-127.36B-
Financing Cash Flow8.07B12.58B39.17B-74.20M25.53B1.03B73.61B-26.90B-47.81M-852.54M136.78B-
Capital Expenditure608.88M334.95M2.98B21.85B10.14B5.01B3.10B698.60M1.72B868.52M1.41B3.00B
Free Cash Flow------16.31B-16.72B-11.39B-13.44B-12.97B-14.93B-23.58B
FCF to OCF-----169.93%123.40%107.30%114.64%118.19%116.95%114.56%

Earnings

Report DateSep 30, 2015Mar 15, 2016May 16, 2016Aug 16, 2016Nov 14, 2016Mar 17, 2017May 15, 2017Aug 15, 2017Nov 14, 2017Feb 9, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 8, 2019May 15, 2019Aug 14, 2019Nov 13, 2019Feb 7, 2020May 15, 2020Aug 14, 2020Nov 16, 2020Feb 5, 2021May 17, 2021Aug 13, 2021Nov 15, 2021Feb 4, 2022May 13, 2022Aug 16, 2022Nov 14, 2022Mar 17, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 20, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Mar 18, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 18, 2026May 13, 2026Jun 30, 2026
EPS Estimate--------------------------------------------
EPS Actual-54.54-55.07-59.87-49.84-47.84-55.76-79.42-74.97-54.34-70.70-98.16-103.72-154.47-103.00-134.08-191.28-227.99-617.39-227.27-343.28-267.36-314.78-251.48-76.85-207.49-193.43-98.38-178.04-147.56-306.27-194.49-218.97-201.39-158.70-196.11-398.18-231.66-234.70-143.03-163.53-87.16-201.35-263.08-331.84
Surprise--------------------------------------------
Timing-After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market----Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap2.15T
Enterprise Value2.10T
Trailing P/E0.00
Forward P/E0.00
Price / Sales368.91
Price / Book16.57
Revenue (TTM)5.81B
Gross Profit (TTM)4.47B
EBITDA-10.74B
Profit Margin-219.16%
Operating Margin-244.81%
Return on Equity-2363.07%
Return on Assets-11.93%
Shares Outstanding15.33M
Shares Float18.46M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 13, 2020759:721
  • Jul 25, 20182:1